UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

Office of the Director
Bureau of Competition

April 30, 2024

NDA	Product(s)	Proprietary Name	Patent Number	Listing Type
209637	1, 2, 3, & 4	Ozempic	7762994	DP
			8684969	DP
			8920383	DP
			9108002	DP
			9132239	DP
			9457154	DP
			9616180	DP
			9687611	DP
			9775953	DP
			9861757	DP
			10220155	DP
			10357616	DP
			10376652	DP
			11097063	DP
			11311679	DP
			11446443	DP
			RE46363	DP
NDA	**Product(s)**	**Proprietary Name**	**Patent Number**	**Listing Type**
206321	1	Saxenda	7762994	DP
			8684969	DP
			8920383	DP
			9108002	DP
			9132239	DP
			9457154	DP
			9616180	DP
			9687611	DP
			9775953	DP
			9861757	DP
			10220155	DP
			10357616	DP
			10376652	DP
			11097063	DP

			11311679	DP
			11446443	DP
			RE46363	DP
NDA	**Product(s)**	**Proprietary Name**	**Patent Number**	**Listing Type**
22341	1	Victoza	7762994	DP
			9265893	DP

As the Policy Statement explains, patents improperly listed in the Orange Book may delay lower-cost generic drug competition. By listing their patents in the Orange Book, brand drug companies may benefit from an automatic, 30-month stay of FDA approval of competing generic drug applications.[4] In addition to delays resulting from ng f, i tht(, 4 (t.s)-4 (l)(l)-2 (r)3 (e)4 (s)-9i)(tht(

Sincerely,

/s/ Rahul Rao
Deputy Director
Bureau of Competition

Enclosure: FTC Policy Statement Concerning Brand Drug Manufacturers Improper Listing of Patents in the Orange Book